
Erloglob 150mg Tablet
Marketer
Globela Pharma Pvt Ltd
Salt Composition
Erlotinib (150mg)
Overview Erloglob 150mg Tablet
Erloglob 150mg tablets treat non-small cell lung and pancreatic cancers. Administer on an empty stomach, or one hour before or two hours after meals. Continue treatment as directed by your physician; duration depends on individual response. Follow your doctor's instructions precisely; incorrect usage or overdosage can cause serious adverse effects. Benefits may not be apparent for weeks or months; do not discontinue unless instructed. Common side effects include nausea, vomiting, tiredness, skin rashes, and weight loss. Severe diarrhea should be reported; increase fluid intake or seek medical advice. Photosensitivity may occur; use sun protection. Report mouth sores, vision changes, or breathing problems immediately. Liver function monitoring may be recommended. Inform your healthcare provider of all other medications you are taking, as interactions are possible. Avoid use during pregnancy or breastfeeding; effective contraception is crucial for both partners. Smoking cessation is advised as it can interfere with the medication's efficacy. Maintain a two-hour interval between Erloglob and antacids or other medications.
Primary Ingredients of Erloglob 150mg Tablet
There is no text provided to rephrase.
Uses of Erloglob 150mg Tablet
Cancers of the pancreas and non-small-cell lung
Major Benefits of Erloglob 150mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the entire tablet; avoid chewing, crushing, or breaking it. Erloglob 150mg Tablets should be taken on an empty stomach.
Common Side effects of Erloglob 150mg Tablet:
- Abdominal pain
- Bone pain
- Breathlessness
- Constipation
- Cough
- Diarrhea
- Fatigue
- Fever
- Infection
- Muscle pain
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weight loss
How to use Erloglob 150mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 150mg Erloglob tablet whole; avoid chewing, crushing, or breaking it. Administer on an empty stomach.
How Erloglob 150mg Tablet works:
Erloglob 150mg tablets combat lung cancer by targeting epidermal growth factor receptors (EGFR). These receptors, located on the surface of lung cancer cells, regulate their proliferation. The drug's mechanism involves binding to EGFR, thereby blocking the cancer's EGFR-dependent signaling pathways and halting its expansion.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Erloglob 150mg Tablet may pose unknown risks. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using Erloglob 150mg tablets during pregnancy poses a confirmed risk to the fetus. Therefore, it's contraindicated. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Breastfeeding while taking Erloglob 150mg tablets is likely inadvisable. Available human data indicates potential drug transfer to breast milk, posing a risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of Erloglob 150mg Tablet on driving ability is undetermined. Refrain from operating a vehicle if you exhibit symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Erloglob 150mg tablets are considered safe for patients with kidney disease, and no dosage modification is necessary. However, this medication is contraindicated for individuals with severe kidney impairment.
LiverCAUTION
Patients with hepatic impairment should use Erloglob 150mg tablets cautiously; dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Erloglob 150mg Tablet :
Omit any missed Erloglob 150mg Tablet dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Erloglob 150mg Tablet
| Label | Value |
|---|---|
| Chemical Category | Quinazoline-based Compound |
| Developing Habits | No. |
| Type of Treatment | Cancer Medications |
